ADO and renal cell carcinoma: Several ongoing clinical trials are being conducted to investigate the effects of targeting the ADO pathway in RCC (e.g., NCT03454451, NCT04306900, NCT04262375, NCT02655822, NCT03207867, NCT04306900, NCT03549000).